Researcher

Associate Professor Carsten Schmitz-Peiffer

Keywords

Fields of Research (FoR)

Biochemistry and Cell Biology, Cell Metabolism, Signal Transduction

SEO tags

Biography

Research Interests:
The development of insulin resistance in skeletal muscle and liver is a key feature in the pathogenesis of type 2 diabetes. Insulin resistance is strongly associated with increased lipid availability, although the precise mechanisms involved remain to be elucidated. The Insulin Signalling Group at the Garvan Institute employs animal and cell culture models to study lipid metabolism and the inhibitory signalling pathways...view more

Research Interests:
The development of insulin resistance in skeletal muscle and liver is a key feature in the pathogenesis of type 2 diabetes. Insulin resistance is strongly associated with increased lipid availability, although the precise mechanisms involved remain to be elucidated. The Insulin Signalling Group at the Garvan Institute employs animal and cell culture models to study lipid metabolism and the inhibitory signalling pathways initiated by lipids which interfere with normal insulin action, with an interest in crosstalk between different tissues such as adipose tissue, the brain and liver. We are also developing small molecules inhibitors against a target we have identified in the development of glucose intolerance.

Broad Research Areas:
Diabetes, Obesity, Biochemistry, Metabolism, Proteomics

Qualifications:
BA (Natural Sciences) Cambridge, UK; PhD (Biochemistry) Bristol, UK

Specific Research Keywords:
Type 2 diabetes, Signalling and Transcription, Endocrinology, Molecular Mechanisms, Cell Metabolism


My Grants

Carsten Schmitz-Peiffer has obtained over $3 million in peer-reviewed grant funding as CIA. He has been awarded 6 NHMRC project grants as CIA since 2003, and an NHMRC Development Grant as CIB (2007). He has also received funding from Diabetes Australia Research Trust (9 grants since 2002), Eli Lilly Endocrinology Research Grants (2 grants) and a recent Perpetual Impact Grant (2019-2020) as CIA.

 

NHMRC

2015-2019 NHMRC Project Grant $872,512

Action of PKC epsilon in Adipose Tissue Regulates Hepatic Glucose Production

CIA: C. Schmitz-Peiffer, CIB: T.J. Biden

 

2011-2013 NHMRC Project Grant $583,390

Targeting ceramide metabolism to improve insulin resistance

CIA: C. Schmitz-Peiffer, CIB: T. Mitchell

 

2009-2011 Project Grant $622,500

The regulation of insulin action in liver and skeletal muscle by Protein kinase C epsilon

CIA: C. Schmitz-Peiffer, CIB: T.J. Biden

 

2008-2010 Project Grant $483,750

Dilinoleoyl phosphatidic acid as a novel mediator of insulin resistance in muscle.

CIA: C. Schmitz-Peiffer, CIB: T. Mitchell

 

2006-2008 Project Grant $614,625

Investigation of the roles of Protein Kinase Cε in insulin secretion and insulin clearance.

CIA: C. Schmitz-Peiffer, CIB: T.J. Biden

 

2007 Development Grant $154,500

Therapeutic Strategies and Screening Methods for PKC epsilon antagonists in the treatment of Type 2 diabetes

CIA: T.J. Biden,  CIB: C. Schmitz-Peiffer

 

2003-2005 New Investigator Grant $450,000

The Role of Protein Kinase Cε in the Generation of Lipid-Induced Insulin Resistance in Skeletal Muscle

CIA: C. Schmitz-Peiffer

 

Other Grants

2019-2020       Perpetual Impact Grant $65,000

Identifying new dual action therapies for the treatment of type 2 diabetes

Chief Investigator: C. Schmitz-Peiffer

 

2019    Diabetes Australia Research Trust $60,000

Using Biosensors To Determine the Role of PKCε in Adipose Tissue

Chief Investigator: C. Schmitz-Peiffer

 

2018    Diabetes Australia Research Trust $60,000

Dual Deletion of PKCepsilon and CerS6 in Adipose Tissue to Protect Insulin Sensitivity

Chief Investigator: C. Schmitz-Peiffer

 

2016   Diabetes Australia Research Trust $60,000

Inhibitors of Protein Kinase C Epsilon (PKCe) for the Treatment of Type 2 Diabetes

Chief Investigators: R. Norton, C. Schmitz-Peiffer

 

2015    Diabetes Australia Research Trust $60,000

The role of protein kinase C in the regulation of lipid metabolism and glucose homeostasis

Chief Investigator: C. Schmitz-Peiffer

 

2012    Diabetes Australia Research Trust $39,000

The role of branched chain amino acid degradation in the improvement of glucose homeostasis caused by protein kinase C epsilon deletion

Chief Investigator: C. Schmitz-Peiffer

 

2011    Diabetes Australia Research Trust $60,000

Regulation of Insulin Receptor Function by PKC epsilon

Chief Investigator: C. Schmitz-Peiffe

 

2008    Eli Lilly Endocrinology Research Grant, $40,000

Project: Inhibition of lysophosphatidic acid acyl transferase (LPAAT) as a treatment for insulin resistance and Type 2 diabetes

Chief Investigator: C. Schmitz-Peiffer

 

2007    Rebecca L. Cooper Medical Research Foundation

Equipment Grant: $20,000

Chief Investigator: C. Schmitz-Peiffer

 

2006    Diabetes Australia Research Trust, $30,000

Project: Investigation of the role of Protein Kinase Cε in insulin clearance.

Chief Investigator: C. Schmitz-Peiffer

 

2005    Eli Lilly Endocrinology Research Grant, $30,000

Project: The Role Of The Protein Kinase mTOR In Lipid-Induced Insulin Resistance In Skeletal Muscle Cells

Chief Investigator: C. Schmitz-Peiffer

 

2004    Diabetes Australia Research Trust, $40,000

Project: Inhibitory Regulation of Glycogen Synthase by Unsaturated Fatty Acid

Chief Investigator: C. Schmitz-Peiffer

 

2002    Diabetes Australia Research Trust, $40,000

Project: Unsaturated Fatty Acid, PKC And n-3 Fatty Acid Effects On Insulin Signalling.

Chief Investigator: C. Schmitz-Peiffer

 

Support for Translational Projects

2015 European Lead Factory Public Target Programme ELFSC13_04

Inhibitors Of the interaction of PKCe and RACK2 As Agents For The Treatment Of T2D

ELF to perform HTS AlphaScreen for inhibitors of PKCε-RACK2 interaction, confirm hits, deselect non-specific hits, dose response curve, selectivity profile, orthogonal assays.

Chief Investigators: Dr Graeme Wilkinson (The Research Network, UK); C. Schmitz-Peiffer

 

2014 AstraZeneca / Academic Drug Discovery Consortium

Free access to ready-to-screen 250,000 compound library worth $130,000

Inhibitors of protein kinase C epsilon as agents for the treatment of type 2 diabetes

Chief Investigators: C. Schmitz-Peiffer, J. Baell, K. Laclovic, T.J. Biden

 

2012  Regeneus Pty Ltd, $30,000

Mesenchymal stem cells as a therapy for Type 2 diabetes

Chief Investigator: C. Schmitz-Peiffer

 

2010    Garvan Institute Business Development funding $97,000

Use of peptide inhibitors of PKCε to treat glucose intolerance

Chief Investigators: T.J. Biden, C. Schmitz-Peiffer

 

2006    Devgen NV, $20,000

Treatment of pancreatic β-cell dysfunction and insulin resistance by inhibition of PKCε

Chief Investigators: C. Schmitz-Peiffer, T.J. Biden


My Qualifications

BA (Natural Sciences) Cambridge, UK

PhD (Biochemistry) Bristol, UK


My Awards

Garvan Institute High Impact Publication Prize 2019

Garvan Institute High Impact Publication Prize 2007

 


My Research Supervision


Supervision keywords


Areas of supervision

ILP, Honours Masters PhD


Currently supervising

As a member of the Garvan Institute Higher Degree Committee since 2009, I am integrally involved in higher degree management. I have successfully supervised six PhD students, an MSc and two honours students.

View less

Location

Diabetes and Metabolism Division
Level 6, Garvan Institute
384 Victoria Street
DARLINGHURST NSW 2010

Contact

02 9295 8212
92958201